Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 1 to 10 of 112 total matches.

Comparison Chart: Correct Use of Inhalers for Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
inhaler ▶ Drug delivery to the lungs is dependent upon ability to perform a rapid, deep inhalation ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8   doi:10.58347/tml.2024.1716c |  Show IntroductionHide Introduction

Balfaxar: Another Four-Factor PCC for Warfarin Reversal

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent ...
Balfaxar (Octapharma), a human plasma-derived four-factor prothrombin complex concentrate (PCC), has been approved by the FDA for rapid reversal of warfarin anticoagulation in adults who require an urgent surgical/invasive procedure. It is the second four-factor PCC to become available in the US; Kcentra, which has been available since 2013, is approved for the same indication and for urgent reversal of warfarin anticoagulation in adults with acute major bleeding. Balfaxar is marketed in Canada and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2   doi:10.58347/tml.2024.1696d |  Show IntroductionHide Introduction

Table: Correct Use of Inhalers for COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020  (Issue 1606)
powder inhaler Drug delivery to the lungs is dependent upon ability to perform a rapid, deep inhalation ...
View the Table: Correct Use of Inhalers for COPD
Med Lett Drugs Ther. 2020 Sep 7;62(1606):e150-4 |  Show IntroductionHide Introduction

In Brief: New Labeling for Once-Monthly Subcutaneous Buprenorphine (Sublocade)

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025  (Issue 1726)
buprenorphine (rapid induction) or 7-14 days of transmucosal treatment (standard induction). The rate ...
The FDA has approved changes to the labeling of Sublocade (Indivior), an extended-release formulation of the partial opioid agonist buprenorphine, to permit faster initiation and use of alternative injection sites. Sublocade is indicated for once-monthly subcutaneous treatment of moderate to severe opioid use disorder.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):63-4   doi:10.58347/tml.2025.1726e |  Show IntroductionHide Introduction

Lyumjev - A New Insulin Lispro for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
in 2017.1 THE NEW PRODUCT — Lyumjev contains insulin lispro (Humalog, and generics; Admelog2), a rapid ...
The FDA has approved insulin lispro-aabc (Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog), for treatment of type 1 and type 2 diabetes in adults. Fiasp, a faster-acting formulation of insulin aspart (Novolog), was approved in 2017.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):162-3 |  Show IntroductionHide Introduction

Terlipressin (Terlivaz) for Hepatorenal Syndrome

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023  (Issue 1672)
in adults with hepatorenal syndrome (HRS) and a rapid decline in kidney function. Terlipressin ...
The FDA has approved the intravenously administered synthetic vasopressin analog terlipressin (Terlivaz – Mallinckrodt) to improve kidney function in adults with hepatorenal syndrome (HRS) and a rapid decline in kidney function. Terlipressin is the first drug to be approved for this indication in the US; it has been available in Europe and elsewhere for year
Med Lett Drugs Ther. 2023 Mar 20;65(1672):46-8   doi:10.58347/tml.2023.1672c |  Show IntroductionHide Introduction

In Brief: A Home Test for Chlamydia, Gonorrhea, and Trichomoniasis

   
The Medical Letter on Drugs and Therapeutics • May 12, 2025  (Issue 1728)
for chlamydia and gonorrhea. JAMA 2024; 331:1701. 2. SR Morris et al. Performance of a single-use, rapid, point ...
The FDA has authorized use of the Visby Medical Women's Sexual Health Test (Visby), an at-home test available without a prescription, for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis infections in women with and without symptoms. It is the first test to become available in the US for these sexually transmitted infections (STIs) that can be performed entirely at home. Other at-home tests are available in the US for diagnosis of chlamydia, gonorrhea, and trichomoniaisis, but they require mailing a urine or blood sample to a...
Med Lett Drugs Ther. 2025 May 12;67(1728):80   doi:10.58347/tml.2025.1728e |  Show IntroductionHide Introduction

Tramadol Oral Solution (Qdolo) for Pain

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
may not experience an analgesic effect and CYP2D6 ultra-rapid metabolizers may have more adverse effects. Table 1 ...
The opioid agonist tramadol is now available in an oral solution (Qdolo – Athena Bioscience) for management of pain severe enough to require an opioid and for which alternative treatment options are inadequate. Tramadol has been available for years in immediate-release tablets and capsules, extended-release capsules (Ultram, and others), and in a fixed-dose combination tablet with acetaminophen (Ultracet, and generics).
Med Lett Drugs Ther. 2021 May 31;63(1625):83-4 |  Show IntroductionHide Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
coordination ▶ DPIs require ability to perform a rapid, deep inhalation 36.00 57.00 68.20 26.407 ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7   doi:10.58347/tml.2024.1710b |  Show IntroductionHide Introduction

Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
; also called Berger's disease) who are at risk of rapid disease progression. It is the first drug ...
The FDA has approved Tarpeyo (Calliditas), a delayed-release capsule formulation of the corticosteroid budesonide, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk of rapid disease progression. It is the fi rst drug to be approved in the US for this indication. Oral formulations of budesonide have been available for years for treatment of inflammatory bowel disease.
Med Lett Drugs Ther. 2022 May 16;64(1650):76-7 |  Show IntroductionHide Introduction